RenovoRx logo

RenovoRx (RNXT) Q1 2025 Earnings

RNXT·Reported May 15, 2025·After market close

RenovoRx reported Q1 2025 revenue of $197.0K, beat analyst consensus of $183.3K by $13.7K. Diluted EPS came in at $-0.08 (-14.3% YoY).

Revenue
$197.0Kbeat by $13.7K
Consensus: $183.3K
Diluted EPS
$-0.08met estimate
Consensus: $-0.08
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001641172-25-010935

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about RenovoRx's Q1 2025 earnings report.

RenovoRx (RNXT) reported Q1 2025 earnings on May 15, 2025 after market close.

RenovoRx reported revenue of $197.0K and diluted EPS of $-0.08 for Q1 2025.

Revenue beat the consensus estimate of $183.3K by $13.7K. EPS beat the consensus estimate of $-0.08 by $0.00.

Compared to the same quarter a year prior, diluted EPS declined 14.3% from $-0.07.

You can read the 10-Q periodic report (0001641172-25-010935) directly on SEC EDGAR. The filing index links above go to sec.gov.